Clinical Trials Directory

Trials / Completed

CompletedNCT00389909

Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants

Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
85 (actual)
Sponsor
Jean Michel Hascoet · Academic / Other
Sex
All
Age
1 Week – 3 Months
Healthy volunteers
Not accepted

Summary

Doxapram is used to stimulate respiration. For a given dose, the fluctuations in concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of this study is to compare a dosage regimen based only on patient's weight, to another one using a dosing chart taking into account weight, age and gender.

Detailed description

Doxapram is a drug used to stimulate respiration in neonates prematurely born and failing to breathe. For a given dose, the fluctuations in concentrations of drug observed in infants' blood might be wide, leading to a risk of lack of efficacy of the treatment or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of our study is to compare a dosage regimen based only on patient's weight, and another one using a dosing chart taking into account not only weight but also age and gender to prescribe the initial dose of doxapram. The final goal of this trial is to improve efficacy and tolerance of doxapram by minimizing the fluctuations in blood drug levels in premature neonates.

Conditions

Interventions

TypeNameDescription
DRUGDoxapramDosing comparison between fixed scheduled and sex related dosage. Dosing related to weight only versus chart taking into account weight, age and gender.

Timeline

Start date
2006-11-01
Primary completion
2010-11-01
Completion
2010-11-01
First posted
2006-10-19
Last updated
2017-02-27

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00389909. Inclusion in this directory is not an endorsement.